ArticleInternational journal of nanomedicine2026
Antigen-Containing Silk Nanoparticles: A New Potential as Oral Vaccine Carriers.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Oral vaccines are safer, easier to administer, and more cost-effective than injectable vaccines are. They induce systemic and mucosal immunity, thereby providing broad protection. However, developing an orally administered vaccine that can traverse the stomach and safely reach the intestinal tract to induce antigen-specific immune responses is challenging. Recently, many effective nanoparticle (NP) drug delivery systems have been developed. Various polymeric materials, including synthetic biodegradable and natural polymers, have been used as drug delivery matrices. Silk fibroin, a natural polymer, shows promise as a suitable material for drug delivery due to its biocompatibility, biodegradability, and aqueous processability. In this study, to investigate the potential of silk proteins as oral vaccine carriers, we prepared ovalbumin (OVA)-containing silk NPs through salting-out an aqueous solution of degummed fibers and non-degummed cocoons obtained from silkworms ( Methods: For the OVA-containing silk NPs, OVA was prepared through salting-out a mixture of OVA and an aqueous solution of cocoons or degummed fibers. OVA-specific antibody production in mice orally administrated OVA-containing silk NPs was analyzed using ELISA. Silk NP delivery to the intestinal tract of mice was monitoring using FITC-incorporated silk. The FITC-labeled cocoon and degummed fiber NPs were incubated with peritoneal macrophages, and their internalization observed using fluorescence imaging. Results: OVA-containing silk NPs can be delivered to the intestinal tract after oral administration to mice and subsequently induce OVA-specific serum IgG and intestinal IgA production without the need for adjuvants. Moreover, internalization of FITC-labeled cocoon or degummed fiber NPs into peritoneal macrophages was observed in vitro. Conclusion: Overall, silk NPs are promising oral vaccine carriers that can deliver antigens to the intestinal tract while avoiding decomposition by gastric acid and digestive enzymes, thereby facilitating the activation of mucosal and systemic immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.